AbbVie's ELAHERE Shows 62.7% Response in Phase 2 Platinum-Sensitive Ovarian Cancer Trial
Summary
AbbVie announced positive Phase 2 trial results for its antibody-drug conjugate, mirvetuximab soravtansine-gynx (ELAHERE), in combination with carboplatin for platinum-sensitive ovarian cancer. The trial achieved an objective response rate of 62.7% in patients with high folate receptor alpha expression, maintaining a consistent safety profile. This development is distinct from recent financial guidance adjustments and legal challenges, representing a new positive catalyst for the company's pipeline. These strong Phase 2 results indicate a potential expansion of ELAHERE's market beyond its current approval for platinum-resistant ovarian cancer, which could significantly boost its revenue potential and reinforce AbbVie's oncology franchise. Investors will be watching for further clinical development and regulatory progress for this expanded indication.
At the time of this announcement, ABBV was trading at $208.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $367.8B. The 52-week trading range was $164.39 to $244.81. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.